Macrocure (MCUR) Reports In-Line Q2 EPS

Macrocure (NASDAQ: MCUR) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37).

Total cash position as of June 30, 2015 was $35.9 million.

"This quarter we advanced our two pivotal Phase III clinical trials of our lead product candidate CureXcell. We remain on track to receive futility analysis results in the VLU trial in August and report top-line study results in the first half of 2016. We are also pleased to report progress towards the completion of our DFU trial, which remains on track to report top-line results in October 2015," stated Nissim Mashiach, President and Chief Executive Officer of Macrocure.

"The VLU futility analysis is an important milestone for Macrocure and will be performed on data from 60%, or approximately 160, of patients who have been randomized and completed treatment. The main purpose of this analysis, apart from ongoing safety, is to assess the probability of success of the trial based on conditional power. The futility results will constitute a significant efficacy and safety signal that will provide clarity in our ongoing VLU pivotal study. We look forward to reporting the results later this month," concluded Mr. Mashiach.

For earnings history and earnings-related data on Macrocure (MCUR) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Summit Financial Group (SMMF) Tops Q1 EPS by 7c
• AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line